Adaptimmune Set To Join Rush Of Cancer-Focused IPOs
Venture capital-backed Adaptimmune Therapeutics PLC fine-tuned plans Monday to raise $150 million in its initial public offering, setting the stage for the U.K.-based immunotherapy treatment developer to become the latest cancer-focused...To view the full article, register now.
Already a subscriber? Click here to view full article